Document Detail

Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells.
MedLine Citation:
PMID:  12171904     Owner:  NLM     Status:  MEDLINE    
In previous experiments, 125I-labeled 1F5 (anti-CD20)was found to kill B-lymphoma cells efficiently and specifically.Unexpectedly, the number of antibody (Ab) molecules taken up per cell was much larger than the number of antigen sites on the cell surface. The present studies were designed to explain this apparent discrepancy. Incubation with fluorophore-conjugated 1F5, using the Raji cell line, demonstrated that the Ab accumulated in large amounts in a juxtanuclear spot. Double labeling showed that the same spot was labeled by transferrin, but the transferrin labeling was much faster (45 min versus 18 h). Experiments with brefeldin A demonstrated that the spot stained was distinct from the Golgi cisternae; thus, it appears to be the endocytic recycling compartment. A fluorescent Fab fragment of 1F5 produced much weaker, barely detectable staining of the juxtanuclear spot. Experiments with three other B-lymphoma cell lines demonstrated marked heterogeneity among them. With Ramos cells, 1F5 and transferrin localized to multiple smaller intracellular spots, rather than a single large spot. There were also major differences between different Abs to CD20, as tested on Raji cells. Rituximab showed some staining of the juxtanuclear spot, but not as homogeneously as the staining with 1F5. B1 and L27 were not tested as thoroughly but did not appear to stain the juxtanuclear spot. Such internalization may have a major impact on the therapy of this tumor type with conjugates of anti-CD20 Abs. However, internalization did not correlate with sensitivity to specific killing by 125I-labeled 1F5.
Rosana B Michel; M Jules Mattes
Related Documents :
20384844 - Metabolic crossroads of iron and copper.
9139744 - Ferritin is a developmentally regulated nuclear protein of avian corneal epithelial cells.
7524474 - Iron requirement for cellular dna damage and growth inhibition by hydrogen peroxide and...
15925514 - Human serum transferrin cobalt complex: stability and cellular uptake of cobalt.
3670304 - Transient correction of genetic defects in cultured animal cells by introduction of fun...
25398614 - Local statistics allow quantification of cell-to-cell variability from high-throughput ...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  8     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2002 Aug 
Date Detail:
Created Date:  2002-08-12     Completed Date:  2003-02-26     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2701-13     Citation Subset:  IM    
Center for Molecular Medicine and Immunology, Belleville, New Jersey 07109, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies / chemistry*
Antibody Specificity
Antigens, CD20 / biosynthesis,  immunology*
Binding, Competitive
Brefeldin A / pharmacology
Dose-Response Relationship, Drug
Electrophoresis, Polyacrylamide Gel
Golgi Apparatus / metabolism
Lymphoma, B-Cell / immunology*,  metabolism
Microscopy, Fluorescence
Protein Binding
Protein Synthesis Inhibitors / pharmacology
Time Factors
Transferrin / metabolism
Tumor Cells, Cultured
Ultraviolet Rays
Grant Support
Reg. No./Substance:
0/Antibodies; 0/Antigens, CD20; 0/Epitopes; 0/Protein Synthesis Inhibitors; 11096-37-0/Transferrin; 20350-15-6/Brefeldin A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Next Document:  Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in...